Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathwaysVIS, André N; SCHRÖDER, Fritz H.BJU international (Papier). 2009, Vol 104, Num 4, pp 438-448, issn 1464-4096, 11 p.Article

Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5α-reductaseVIS, André N; SCHRÖDER, Fritz H.BJU international (Papier). 2009, Vol 104, Num 9, pp 1191-1197, issn 1464-4096, 7 p.Article

The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancerVIS, André N; SCHRÖDER, Fritz H; VAN DER KWAST, Theodorus H et al.European urology. 2006, Vol 50, Num 2, pp 258-265, issn 0302-2838, 8 p.Article

Defining the window of opportunity in screening for prostate cancer : Validation of a predictivetumor classification modelVIS, André N; HOEDEMAEKER, Robert F; VAN DER KWAST, Theo H et al.The Prostate. 2001, Vol 46, Num 2, pp 154-162, issn 0270-4137Article

Prostate-specific antigen-based early detection of prostate cancer-validation of screening without rectal examinationSCHRÖDER, Fritz H; ROOBOL-BOUTS, Monique; VIS, André N et al.Urology (Ridgewood, NJ). 2001, Vol 57, Num 1, pp 83-90, issn 0090-4295Article

Should we replace the gleason score with the amount of high-grade prostate cancer?VIS, André N; ROEMELING, Stijn; KRANSE, Ries et al.European urology. 2007, Vol 51, Num 4, pp 931-939, issn 0302-2838, 9 p.Article

Lower Testosterone Levels With Luteinizing Hormone-Releasing Hormone Agonist Therapy Than With Surgical Castration: New Insights Attained by Mass SpectrometryVAN DER SLUIS, Tim M; BUI, Hong N; MEULEMAN, Eric J. H et al.The Journal of urology. 2012, Vol 187, Num 5, pp 1601-1606, issn 0022-5347, 6 p.Article

Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non-Muscle-Invasive Bladder CancerVAN RHIJN, Bas W. G; ZUIVERLOON, Tahlita C. M; ZWARTHOFF, Ellen C et al.European urology. 2010, Vol 58, Num 3, pp 433-441, issn 0302-2838, 9 p.Article

Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies: Early cancers may contain aggressive genetic featuresALERS, Janneke C; KRIJTENBURG, Pieter-Jaap; VIS, André N et al.The American journal of pathology. 2001, Vol 158, Num 2, pp 399-406, issn 0002-9440Article

FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinomaVAN RHIJN, Bas W. G; VAN DER KWAST, Theo H; VIS, André N et al.Cancer research (Baltimore). 2004, Vol 64, Num 6, pp 1911-1914, issn 0008-5472, 4 p.Article

Molecular grading of urothelial cell carcinoma with Fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcomeVAN RHIJN, Bas W. G; VIS, André N; VAN DER KWAST, Theo H et al.Journal of clinical oncology. 2003, Vol 21, Num 10, pp 1912-1921, issn 0732-183X, 10 p.Article

Significance of Tertiary Gleason Pattern 5 in Gleason Score 7 Radical Prostatectomy Specimens. CommentaryWHITTEMORE, Darren E; HICK, Eric J; CARTER, Mark R et al.The Journal of urology. 2008, Vol 179, Num 2, pp 516-522, issn 0022-5347, 7 p.Article

Detection of prostate cancer : A comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsyVIS, André N; BOERMA, Michiel O; CIATTO, Stefano et al.Urology (Ridgewood, NJ). 2000, Vol 56, Num 4, pp 617-621, issn 0090-4295Article

Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screeningtest at low PSA (0.0-3.9 ng/ml)VIS, André N; HOEDEMAEKER, Robert F; ROOBOL, Monique et al.The Prostate. 2001, Vol 47, Num 4, pp 252-261, issn 0270-4137Article

Pathologic features of prostate cancer found at population-based Screening with a four-year intervalHOEDEMAEKER, Robert F; VAN DER KWAST, Theodorus H; BOER, Rob et al.Journal of the National Cancer Institute. 2001, Vol 93, Num 15, pp 1153-1158, issn 0027-8874Article

Prognostic value of cell cycle proteins p27^kip1 and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancerVIS, André N; NOORDZIJ, Marinus A; FITOZ, Kubilay et al.The Journal of urology. 2000, Vol 164, Num 6, pp 2156-2161, issn 0022-5347Article

Relationship Between Body Mass Index and Serum Testosterone Concentration in Patients Receiving Luteinizing Hormone-releasing Hormone Agonist Therapy for Prostate CancerVAN DER SLUIS, Tim M; VAN MOORSELAAR, R. Jeroen A; MEULEMAN, Eric J. H et al.Urology (Ridgewood, NJ). 2013, Vol 81, Num 5, pp 1005-1009, issn 0090-4295, 5 p.Article

Metastatic disease of screen-detected prostate cancer : Characteristics at diagnosisROEMELING, Stijn; KRANSE, Ries; VIS, André N et al.Cancer. 2006, Vol 107, Num 12, pp 2779-2785, issn 0008-543X, 7 p.Article

The predictive value for prostate cancer of lesions that raise suspicion of concomitant carcinoma: an evaluation from a randomized, population-based study of screening for prostate cancerVIS, Andre N; HOEDEMAEKER, Robert F; ROOBOL, Monique et al.Cancer. 2001, Vol 92, Num 3, pp 524-534, issn 0008-543XArticle

Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section RotterdamVAN DER CRUIJSEN-KOETER, Ingrid W; VIS, Andre N; ROOBOL, Monique J et al.The Journal of urology. 2005, Vol 174, Num 1, pp 121-125, issn 0022-5347, 5 p.Article

Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancerVAN DER SLUIS, Tim M; VIS, Andre N; VAN MOORSELAAR, R. Jeroen A et al.BJU international (Papier). 2012, Vol 109, Num 2, pp 176-182, issn 1464-4096, 7 p.Article

Cancer detection and Cancer characteristics in the European randomized study of Screening for Prostate Cancer (ERSPC) - section Rotterdam a comparison of two rounds of ScreeningPOSTMA, Renske; SCHRÖDER, Fritz H; VAN LEENDERS, Geert J. L. H et al.European urology. 2007, Vol 52, Num 1, pp 89-97, issn 0302-2838, 9 p.Article

Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancerVAN DER SLUIS, Tim M; MEULEMAN, Eric J. H; VAN MOORSELAAR, R. Jeroen A et al.BJU international (Papier). 2012, Vol 109, Num 2, pp 183-188, issn 1464-4096, 6 p.Article

The FGFR3 Mutation is Related to Favorable pT1 Bladder CancerVAN RHIJN, Bas W. G; DER KWAST, Theo H. Van; ZLOTTA, Alexandre R et al.The Journal of urology. 2012, Vol 187, Num 1, pp 310-314, issn 0022-5347, 5 p.Article

Prognostic value of molecular markers, sub- stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancerRHIJN, Bas W. G. Van; LIYANG LIU; ZWARTHOFF, Ellen C et al.BJU international (Papier). 2012, Vol 110, Num 8, pp 1169-1176, issn 1464-4096, 8 p.Article